These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34857678)

  • 1. Paclitaxel-induced stress granules increase
    Shi X; Si X; Zhang E; Zang R; Yang N; Cheng H; Zhang Z; Pan B; Sun Y
    J Biomed Res; 2021 Oct; 35(6):411-424. PubMed ID: 34857678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
    Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
    J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Chiu HW; Lin HY; Tseng IJ; Lin YF
    Oncotarget; 2018 Jan; 9(1):553-565. PubMed ID: 29416635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
    Chen J; Zhu M; Zou L; Xia J; Huang J; Deng Q; Xu R
    Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):801-809. PubMed ID: 32632453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3a mediates paclitaxel-induced abnormal expression of LINE-1 by increasing the intragenic methylation.
    Wang XY; Zhang Y; Yang N; Cheng H; Sun YJ
    Yi Chuan; 2020 Jan; 42(1):100-111. PubMed ID: 31956100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
    Lin YF; Tseng IJ; Kuo CJ; Lin HY; Chiu IJ; Chiu HW
    J Cell Mol Med; 2018 Apr; 22(4):2458-2468. PubMed ID: 29392887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
    Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
    Adjibade P; St-Sauveur VG; Quevillon Huberdeau M; Fournier MJ; Savard A; Coudert L; Khandjian EW; Mazroui R
    Oncotarget; 2015 Dec; 6(41):43927-43. PubMed ID: 26556863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
    Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
    J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
    Gote V; Sharma AD; Pal D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
    Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long interspersed nuclear element ORF-1 protein promotes proliferation and resistance to chemotherapy in hepatocellular carcinoma.
    Feng F; Lu YY; Zhang F; Gao XD; Zhang CF; Meredith A; Xu ZX; Yang YT; Chang XJ; Wang H; Qu JH; Zeng Z; Yang JL; Wang CP; Zhu YF; Cui JJ; Yang YP
    World J Gastroenterol; 2013 Feb; 19(7):1068-78. PubMed ID: 23466962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 20. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.